News and insights
223 81 Lund, Sverige
+46 46-15 21 00
©Copyright 2022 CLS AB. All rights reserved.
At CLS, we aim at getting doctors as close as possible to the clinical problem and provide the means needed for solving it – without causing another. We do this by providing precise tools for image-guided laser-mediated thermal ablations.
Thermal ablation is used for treatment and removal of diseased or abnormal soft tissues, such as malignant tumors (cancer) or epileptogenic foci. The procedure is minimally invasive and can therefore be offered also to patients that are considered inoperable in view of traditional open surgery.
CLS has its origins in using laser-mediated thermal ablation for immune stimulating treatment of metastasized (spread) cancer.
Our co-founder professor Karl-Göran Tranberg showed in his scientific research how precise laser-mediated “low temperature-long time” thermal ablation (imILT), of cancer cells, triggered the immune system to track and kill cancer cells throughout the body, the so called abscopal effect.
CLS portfolio of TRANBERG products integrates with common imaging equipment used in hospitals and operates with high precision using state-of-the-art software with assisted procedure guidance, monitoring, and control.
Today, our products are commercially available and routinely used in focal therapy of localized prostate cancer. Treatment of tumors and other lesions in the brain as well as abscopal treatment of metastasized cancer comes next.
This is how we make a difference – by providing precise and accurate tools that can transform today’s standard-of-care and improve patient outcome and quality of life. Carefully precise.
Welcome to Clinical Laserthermia Systems.
Please note that all our products and indications are not yet approved in all markets. Don’t hesitate to contact us for up-to-date market approvals in your area!
Please choose your country or region